A recent article published in the European Journal of Health Economics spotlights the organ drug industry, including some implications of such high-cost drugs.
Despite the high cost of the drugs, the article states, society remains willing to continue funding for rare conditions.
“It has been accepted that OMP are not normal goods, but neither are they luxury goods that you can choose not to have. As a society, we do have an inclination to fund those most in need,” the article states.
To read more, click here.